AUGUSTINE THERAPEUTICS
0722.705.230 · rovalta.com · 20/09/2026
ACTIVE
AUGUSTINE THERAPEUTICS
Financial year 2025 · closed on 31/12/2025
Net result
-14,8 M €
-72.7% YoY
Gross margin
-1,7 M €
+5.0% YoY
Equity
29,0 M €
+328.2% YoY
Workforce
11,0 ETP
+103.7% YoY
Overview
What does AUGUSTINE THERAPEUTICS do?
AUGUSTINE THERAPEUTICS is a Public limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 11,0 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0722.705.230
Incorporation
13/03/2019
Legal form
Public limited company
Registered office
Gaston Geenslaan 3
3001 Leuven · FlandreSee on map
3001 Leuven · FlandreSee on map
Contributed capital
52 329 665,17 €
Latest accounts
31/12/2025
Average workforce
11,0 ETP
Activities (NACE)
Joint committees (1)
- 207
Signals
Solid equityLow riskGood liquidity
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -1,7 M € | +5.0% | -1,7 M € | -238% | -515,8 k € | +74.0% | -2,0 M € | -35.4% | -1,5 M € |
| EBITDA | -3,2 M € | -25.8% | -2,6 M € | -175% | -930,1 k € | +58.3% | -2,2 M € | -48.8% | -1,5 M € |
| Operating result | -15,7 M € | -82.2% | -8,6 M € | -112% | -4,1 M € | -35.2% | -3,0 M € | -72.6% | -1,7 M € |
| Net result | -14,8 M € | -72.7% | -8,6 M € | -106% | -4,2 M € | -33.0% | -3,1 M € | -75.8% | -1,8 M € |
| Balance sheet | |||||||||
| Equity | 29,0 M € | +328% | 6,8 M € | +409% | -2,2 M € | -211% | 2,0 M € | +265% | 541,0 k € |
| Total assets | 30,9 M € | +250% | 8,8 M € | +66.2% | 5,3 M € | +96.1% | 2,7 M € | -39.4% | 4,5 M € |
| Cash | 656,4 k € | -91.5% | 7,8 M € | +104% | 3,8 M € | +141% | 1,6 M € | -39.4% | 2,6 M € |
| Debts | 1,9 M € | -3.8% | 2,0 M € | -72.0% | 7,2 M € | +1044% | 625,9 k € | -81.6% | 3,4 M € |
| Other | |||||||||
| Workforce | 11,0 ETP | +104% | 5,4 ETP | – | – | 0,7 ETP | |||
Estimate
Indicative valuation
As an indication, this company is worth
between 25 M€ and 50 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 9 active · 15 ended
Active mandates
Pascale Florence Geneviève Witz
ActiveClara Campàs Moya
ActiveEmmanuelle Coutanceau
ActiveGerhard Koenig
ActiveMahieddine El Mahdi Ainouche
ActiveAlain Huriez
ActiveSylvain Celanire
ActiveWard Capoen
ActiveEnded mandates
Eureka Consulting LLC
EndedGerhard Koenig
EndedAt this address
Other companies at this address
| Company | CBE no. |
|---|---|
AstriVax Therapeutics● Active | 0787.990.881 |
COULTREON BIOPHARMA● Active | 1019.429.814 |
K5 Therapeutics● Active | 0757.718.072 |
Metaptys● Active | 0554.664.311 |
Montis Biosciences● Active | 0730.979.429 |
Perseus Biomics● Active | 0650.946.412 |
QUOMAK● Active | 0448.488.111 |
ReWind Therapeutics● Active | 0682.626.216 |
| 1040.853.946 | |
Tavira Therapeutics● Active | 0802.591.262 |
VEDRA THERAPEUTICS● Active | 1039.565.628 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Micro model | Micro model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/03/2019 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 22 months |
| Filing date | 05/06/2026 | 21/05/2025 | 27/06/2024 | 29/06/2023 | 07/06/2022 | 31/05/2021 |
| General meeting | 13/05/2026 | 14/05/2025 | 13/06/2024 | 10/05/2023 | 11/05/2022 | 27/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
6 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 13/05/2026 | 05/06/2026 | Dutch | |
| Abridged model | 31/12/2024 | 14/05/2025 | 21/05/2025 | Dutch | |
| Micro model | 31/12/2023 | 13/06/2024 | 27/06/2024 | Dutch | |
| Micro model | 31/12/2022 | 10/05/2023 | 29/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 11/05/2022 | 07/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 27/05/2021 | 31/05/2021 | Dutch |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 25 M€ and 50 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 9 active · 15 ended
Active mandates
Pascale Florence Geneviève Witz
ActiveClara Campàs Moya
ActiveEmmanuelle Coutanceau
ActiveGerhard Koenig
ActiveMahieddine El Mahdi Ainouche
ActiveAlain Huriez
ActiveSylvain Celanire
ActiveWard Capoen
ActiveEnded mandates
Eureka Consulting LLC
EndedGerhard Koenig
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates17/06/2025DIVERSEN - ONTSLAGEN - BENOEMINGEN
- Mandates21/05/2025ONTSLAGEN - BENOEMINGEN
- Mandates12/02/2025STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates01/07/2024STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
- Mandates29/11/2023ONTSLAGEN - BENOEMINGEN
- Mandates20/10/2023ONTSLAGEN - BENOEMINGEN
- Registered office20/09/2023MAATSCHAPPELIJKE ZETEL
- Capital / shares03/01/2023KAPITAAL - AANDELEN
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-14,8 M €↓
- 2024Annual accounts 2024-8,6 M €↓
- 2023Annual accounts 2023-4,2 M €↓
- 2022Annual accounts 2022-3,1 M €↓
- 2021Annual accounts 2021-1,8 M €
- 13/03/2019IncorporationPublic limited company